Humana Maintains FY25 Earnings View Below Market

Humana (HUM) intends to reaffirm its fiscal year 2025 earnings guidance of approximately $14.68 per share, or adjusted earnings of around $16.25 per share, during investor meetings in June, slightly below the Wall Street analyst consensus of $16.35. This comes after the company reported earnings of $9.98 per share and adjusted earnings of $16.21 per share in fiscal 2024. In pre-market trading, Humana shares were down approximately 0.21%.

Analysis

Humana, Inc. plans to reaffirm its fiscal 2025 earnings guidance, projecting earnings per share of approximately $14.68 and adjusted earnings per share of around $16.25. This adjusted EPS guidance of $16.25 is slightly below the Wall Street analyst consensus estimate of $16.35 per share. For context, Humana's fiscal 2024 reported earnings were $9.98 per share, with adjusted earnings at $16.21 per share, indicating the 2025 guidance suggests a marginal increase in adjusted earnings year-over-year. The company will convey this reaffirmation during investor and analyst meetings scheduled between June 2 and June 30. In pre-market activity on the NYSE, Humana shares were observed trading down approximately 0.21% at $230.90, reflecting a neutral to slightly negative immediate market reaction, which aligns with the provided HUM-specific sentiment score of -0.15 despite an overall neutral article sentiment.

Key Decisions for Investors

• Investors should note that Humana's reaffirmed FY25 adjusted EPS guidance of $16.25, while demonstrating stability, is slightly below analyst expectations of $16.35 and shows minimal growth over FY24's $16.21 adjusted EPS, potentially tempering near-term upside expectations.
• Consider monitoring the upcoming June investor meetings for further details on the drivers behind the 2025 guidance and management's outlook, which could provide clarity on the slight variance from consensus and influence future stock performance.
• Given the modest implied growth in adjusted earnings and the slight miss against consensus, investors might evaluate their positions and assess if the current valuation adequately reflects this outlook, especially in comparison to peers in the healthcare sector.